Illustration by Alex Castro / The Verge
A Food and Drug Administration committee will meet in mid-June to review data on COVID-19 vaccines for children six months through five years old, the agency announced Monday. If all goes as expected, it could sign off on the shots for that age group within days of that meeting.
The announcement came just after Pfizer / BioNTech said in a Monday morning press release that three doses of their COVID-19 vaccine produced a strong immune response in children between six months and five years old. They plan to submit the data to the Food and Drug Administration this week.
A preliminary analysis of data from the clinical trial of 1,678 children also showed that the shots were around 80 percent effective at preventing symptomatic COVID-19…
